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Background
Open label randomised controlled trials may be subject to
bias where outcome ascertainment relies on treating clini-
cian decisions. In the setting of a multinational rando-
mised controlled open label phase three pharmaceutical
trial we implemented a rigorous verification algorithm to
mitigate against such bias. We report the impact of the
algorithm’s application on the primary endpoint.
Method
The BEATRICE trial recruited 2591 patients with early
surgically treated triple negative breast cancer from 360
sites in 37 countries into a two way randomisation. The
primary endpoint was investigator reported invasive dis-
ease free survival (IDFS). A novel rigorous 103-step end-
point review algorithm was developed to provide central
ratification in support of, but not mandating locally
reported events.
Results
IDFS events were reported in 393 patients. There was
no statistically significant difference between the arms.
The HR was 0•88 [95% CI 0•72-1•07] prior to algorithm
application compared with 0.87 [95% CI 0.72-1.07]. 393
events, the algorithm input changed dates in 74 (19%),
type of event in 7 (2%) and site of event in 11 (3%). The
event number did not change.
Conclusion
Reassuringly the primary results of this open label RCT
did not change with enhanced independent interrogation
and review of reported endpoints. Current standard trial
reporting procedures appear to be adequate even in the
open label setting.
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